Study at a glance
How might vitamin D affect the way hormone systems work together?
The review examines how signals involving vitamin D link organs and hormone systems. Most experiments changed receptors or hormones in mice. Human cell experiments and a cortisol trial add separate comparisons. The central finding is that keeping one measurement normal does not necessarily mean the whole system is functioning normally.
Can normal blood calcium hide problems with bone minerals?
Mice lacking vitamin D receptors in the intestine absorbed calcium poorly but maintained blood calcium through other responses that made up for the poor absorption. Their bones lost mineral and became more fragile. Removing FGF23, a hormone involved in mineral regulation, caused a different pattern: high phosphate, high active vitamin D and severe illness. Lowering dietary phosphate improved some outcomes without correcting the whole condition.
Did vitamin D signals have the same effect in every tissue?
No. Removing the receptor from cartilage affected bone and kidney signals during early development, with several differences disappearing later. Reducing it in a brain region reduced the ability to handle blood sugar in obese male mice, but not females or mice fed standard laboratory food. Human immune-cell responses depended on the order of hormone exposure. A trial in women with multiple sclerosis did not establish a reliable cortisol or symptom benefit from supplements.
Do these findings show that supplements restore hormone systems?
These studies show specific interactions and compensating responses, not one universal vitamin D effect. Genetic changes that remove the receptor is different from a low vitamin D blood result in a person. A normal blood calcium value cannot by itself establish bone health, but the mouse findings are not a rule for diagnosing problems in people. The studies do not show that supplements restore all hormone systems together or provide an individual treatment plan.
Read the full article below ↓Vitamin D participates in endocrine relationships that can preserve one physiological measurement while allowing another outcome to deteriorate. Mouse experiments involving intestinal vitamin D receptors, FGF23 and cartilage show concrete examples of compensation and disrupted coordination. Central metabolic and human glucocorticoid studies extend the comparison, while also showing why these findings do not establish a universal system-restoring effect of supplementation. For the shorter account, see Vitamin D and Endocrine Coordination: Compensation and Failure: Study Summary.
Coordination must be tested through specific relationships
Vitamin D and Endocrine Crosstalk describes interactions among endocrine systems. In research, however, coordination is not a single measurement. Investigators must identify which signal was altered, which organ or cell responded and which outcome changed. A normal blood concentration, an altered cellular response and a clinical benefit are different findings, even when they belong to an interconnected system.
The studies reviewed here use several interventions: removing VDR from intestinal or cartilage cells, deleting Fgf23 throughout an animal, reducing receptor expression in a hypothalamic region, adding active calcitriol to peripheral immune cells, and giving oral vitamin D3 in a human trial. These interventions cannot be ranked on one simple scale of vitamin D status.
The strongest integrated conclusions are therefore local and conditional. Some experiments directly test a component of a mineral-regulation loop. Others identify a possible interface between hormone signals. The cross-study comparison is an interpretation of these distinct results, not a new experiment demonstrating that every endocrine axis changed together.
This article is an original VD3FL analysis of the cited primary research. Material main texts, tables and figures were examined during the evidence review, including the identified relevant supplements for the intestinal and cartilage studies. The research regimens and genetically modified models described below are not instructions for treatment.
Intestinal VDR loss exposed the cost of preserving blood calcium
Lieben and colleagues removed VDR selectively from the intestine in mice. This reduced vitamin-D-dependent intestinal calcium absorption while leaving receptor signalling in other tissues available. The design differs fundamentally from removing VDR throughout the animal: tissue-specific deletion permits compensatory responses elsewhere to remain active. Tissue-Specific VDR Physiology: Knockout and Rescue Evidence explains how tissue-selective loss and restoration test different causal questions.
Despite impaired absorption, total and ionised serum calcium remained comparable with controls under the principal conditions studied. Serum phosphate was also comparable. At the same time, parathyroid hormone, or PTH, and active vitamin D increased from the post-weaning period. The circulating measurements therefore showed a compensated state rather than absence of a physiological disturbance.
The skeleton did not remain normal. Trabecular bone volume and cortical thickness decreased, cortical porosity increased and mineralisation deteriorated. Spontaneous fractures and healing calluses were reported in 10% of the examined intestinal-knockout animals, compared with none of the controls in that observation. A preserved blood calcium concentration was therefore compatible with a substantial skeletal cost.
This experiment makes a specific point about Vitamin D and Homeostatic Balance. Regulation of a circulating variable can succeed while another tissue pays part of the cost. It does not follow that every normal blood calcium result in a person conceals this particular problem. The finding is evidence from a targeted mouse model, not a diagnostic rule derived from one routine laboratory result.
Resorption and reduced mineral deposition both contributed
The study examined more than mineral release from existing bone. Increased bone-turnover measurements were accompanied by impaired incorporation of calcium into bone matrix. Unmineralised osteoid accumulated, including around osteocytes, and the cortex was less well mineralised. These observations distinguish a loss of mineral already stored from a reduction in the deposition of new mineral.
The antiresorptive intervention strengthened the compensation interpretation. Treating intestinal-knockout mice with zoledronic acid from eight to fourteen weeks increased bone volume but decreased serum calcium, although resorption was not fully normalised. Blocking part of the skeletal release response therefore exposed its contribution to maintaining the circulating measurement. Formation markers also rose in the knockout animals; the phenotype was high turnover with poor mineral storage, not isolated stimulation of breakdown.
The local mechanistic work implicated mineralisation inhibitors, including pathways involving extracellular pyrophosphate, ENPP3, ANK and osteopontin. The interpretation was supported by cellular work and by manipulating VDR in mature osteoblast-lineage cells. It should not be simplified to a statement that every vitamin D signal in bone is harmful; the effect depended on mineral supply, the tissue in which signalling was altered and the exposure conditions.
The turnover evidence was also not uniform across all measurements. Serum CTX, a resorption marker, increased, but some supplementary osteoclast measurements were unchanged or lower. An endpoint describing circulating breakdown products need not match every local cell count. Preserving that distinction prevents the compensation model from being overstated as a rise in every indicator of osteoclast activity.
A mineral-rich rescue diet altered the phenotype. It contained 2% calcium, 1.25% phosphorus and 20% lactose, so it changed several aspects of mineral availability together. The rescue supports the importance of intestinal supply, but it is not an isolated human calcium-supplement experiment. The severe low-calcium condition used elsewhere in the study likewise cannot be equated with ordinary dietary variation in people.
FGF23 deletion revealed a different failure of coordination
Shimada and colleagues deleted Fgf23 throughout mice. FGF23 is a peptide signal central to the mineral-regulation question in this experiment. Unlike intestinal VDR deletion, this intervention removed a circulating regulatory component and produced marked phosphate and active-vitamin-D abnormalities, rather than preserving all the principal blood mineral measurements.
The knockout mice developed high serum phosphate and high calcitriol. Renal expression of the activating enzyme was increased, and the renal phosphate transporter NaPi-2a was more prominent at the relevant tubular surface. Measurements of phosphate handling supported increased renal reabsorption. These results connect the genetic perturbation with both active-vitamin-D production and phosphate retention. Renal transcripts were assessed by Northern blot, transporter location by immunohistochemistry, and phosphate transport by renal-clearance measurements and uptake into isolated brush-border membrane vesicles. In the latter assay, uptake was about 633 versus 396 pmol/mg/min in knockout versus heterozygous animals, with six and five animals respectively.
Heterozygotes retained broadly normal FGF23 concentrations and phenotypes, showing compensation for loss of one allele. In complete knockouts, the activating-enzyme transcript rose from day ten, before the later rise in the catabolic-enzyme transcript. That later catabolic response did not normalise calcitriol. Modest hypercalcaemia appeared from about two weeks.
PTH became suppressed later in the developmental course. However, phosphate was already elevated at earlier time points when PTH had not shown the same decrease. The time sequence argues against treating low PTH as the necessary initial cause of the phosphate abnormality. It is a useful example of how a serial experiment can distinguish a candidate initiating event from a later accompanying response.
The animals also showed poor growth, abnormal bone, increased unmineralised osteoid and early mortality. The systemic phenotype was severe, with death by approximately 13 weeks under the reported standard conditions. These outcomes establish the importance of the disrupted regulatory system, but the intervention changed several interacting processes at once.
Consequently, the study does not prove that calcitriol alone caused every abnormality. Global gene deletion, development, mineral disturbances and severe illness all affect the interpretation. Calling the model a straightforward experiment in ordinary vitamin D deficiency would reverse the exposure context and misdescribe the biology.
Partial dietary rescue did not solve the whole phenotype
A low-phosphate diet lowered serum phosphate and prolonged survival in some Fgf23-null mice. In the small reported group, half survived beyond 13 weeks. Yet severe growth impairment and other abnormalities persisted, and active vitamin D remained elevated. Correcting one circulating abnormality was therefore not equivalent to restoring the whole system.
This is distinct from the intestinal-VDR example. In the intestinal model, a relatively preserved blood concentration coexisted with tissue cost. In the Fgf23 model, lowering an abnormal concentration improved part of the outcome without correcting everything. Both show why one laboratory endpoint cannot stand in for every physiological consequence, but they do so through different interventions and mechanisms.
The dietary result also limits causal attribution. If lowering phosphate does not remove the entire phenotype, phosphate alone is not a complete explanation. It does not automatically identify which other factor accounts for each residual effect. Additional targeted perturbations would be needed to separate those contributions.
The publication reports authors employed by Kirin. That affiliation is part of the source context, not evidence that the results should be discarded. As with the other studies, the interpretation rests on the design, measured comparisons, limitations and extent of independent confirmation.
Cartilage-to-bone signalling added a developmental relationship
Masuyama and colleagues removed VDR from chondrocytes using a cartilage-targeted genetic approach. Chondrocytes are the cartilage cells examined in this model, rather than mature osteoblasts or intestinal cells. The juvenile mice showed reduced vascular and osteoclast recruitment around the developing skeletal region and altered RANKL-associated responses.
The endocrine finding was a reduction in osteoblast-associated FGF23 production, accompanied by higher phosphate and calcitriol. Calcium and PTH did not change in the same way. This shows another selective pattern: disrupting a receptor in one cellular compartment affected a signal produced in another, with consequences extending to mineral regulation.
At fifteen days, circulating FGF23 was 43% lower and renal NPT2a transcript abundance was approximately fourfold higher; renal CYP27B1 also increased, whereas CYP24 and renal VDR transcripts did not. These selective changes connect the cartilage perturbation to a plausible bone-to-kidney feedback route. The hormone and phosphate differences were absent at eight weeks, not just the skeletal changes.
Experiments separated secretion from direct cell contact. Osteoblasts and chondrocytes placed on opposite sides of a permeable membrane still showed less calcitriol-induced FGF23 when the chondrocytes lacked VDR. Both FGF23 RNA in osteoblasts and protein in the culture medium supported the result. Isolated osteoblasts from either genotype retained their direct response, while FGF23 RNA was undetectable in the cultured chondrocytes. This supports a soluble cartilage-derived influence on osteoblast output rather than identifying cartilage as the FGF23 source.
Coculture experiments supported communication between the cell populations, but the cartilage-derived factor responsible for regulating osteoblast FGF23 was not identified. The unknown signal must remain unknown in the account. Preserved responsiveness to PGE2 also argues against describing the cells as universally unable to respond.
Several skeletal differences normalised by eight weeks. Developmental timing is therefore central to the result. The experiment does not establish a lifelong adult phenotype, and it does not show that adult mouse growth plates fuse. It demonstrates a stage-dependent interaction that belongs within Vitamin D and Hormones without becoming a general statement about every hormone-producing tissue.
Masuyama and Lieben came from the same Leuven research programme. They provide complementary tissue-specific experiments, not independent laboratory replication of an identical effect. Their contribution to the synthesis is the contrast between manipulated compartments and outcomes.
Central metabolic coordination was conditional on sex and diet
Beck’s hypothalamic study provides a different type of cross-system connection. Reducing VDR in the PVH-associated neuronal population impaired glucose tolerance in obese male mice. Females and chow-fed animals did not show the same phenotype, and insulin-tolerance tests were not significantly altered in either sex.
The result connects a central receptor perturbation with a peripheral metabolic measurement, but it does not establish clinical insulin resistance or identify every intervening neural and hormonal step. Sim1 targeting outside the PVH, incomplete knockdown and limited animal-level electrophysiology replication constrain anatomical and mechanistic precision.
Acute calcitriol activated a proportion of neurons in both sexes, although the whole-animal glucose phenotype differed by sex. This difference between cellular responsiveness and systemic outcome is relevant to Vitamin D and Neuroendocrine Integration. A cell can respond to a signal without that response predicting a uniform physiological consequence after receptor loss.
The model therefore adds evidence for conditional coordination, not a general rule that vitamin D strengthens every endocrine response. It also differs from changing circulating vitamin D status in people. Genetic receptor manipulation and nutritional supplementation answer different causal questions.
Peripheral glucocorticoid interactions do not establish central feedback repair
Kassi’s human-cell experiments examined peripheral blood mononuclear cells from 12 vitamin-D-deficient women. Prolonged calcitriol pretreatment attenuated selected dexamethasone-associated responses, including GILZ induction and receptor movement into the nucleus. Concurrent exposure did not reproduce the same GILZ effect.
This is a direct cellular example of exposure-sequence-dependent interaction. It fits the molecular level of Vitamin D Signalling Pathways, but it does not measure the hypothalamus, pituitary or adrenal gland working together. FKBP5 expression decreased, arguing against increased FKBP5 as the explanation; receptor-abundance and phosphorylation findings suggested other possibilities. Different assays used different numbers of donors.
The experiment thus supplies evidence of peripheral cross-regulation without showing that oral vitamin D improves human stress adaptation. Direction also matters: attenuating one cellular glucocorticoid output is not synonymous with increasing glucocorticoid sensitivity or improving clinical function. Whether a change is desirable cannot be inferred merely from its occurrence in a culture assay.
Rolf’s human trial offers a complementary clinical boundary. Women with relapsing-remitting multiple sclerosis received vitamin D3 or placebo for approximately 16 weeks. Vitamin D status increased, but the daily cortisol and slope comparisons were null. An unadjusted awakening-response comparison gave p=.044, while the baseline-adjusted result was p=.066. Fatigue and depressive-symptom comparisons also did not establish benefit.
Rolf did not measure a dexamethasone feedback response, ACTH or the peripheral cellular pathway examined by Kassi. Combining the two papers therefore does not demonstrate that one result explains the other. The connection is an explicitly cross-study interpretation, with the missing intervening measurements left visible.
What can be integrated across these experiments
The mineral studies directly show that changes in one component can affect others: intestinal absorption, PTH and calcitriol, renal phosphate handling, skeletal mineralisation and cartilage-to-bone signalling. The central mouse and peripheral human-cell studies add more conditional examples. They do not create a single experiment in which calcium, glucose and stress axes were measured and restored together.
When Normal Blood Calcium Conceals a Skeletal Cost develops the specific distinction between preserved blood calcium and skeletal cost. Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study examines the bone-cell and fracture evidence in greater detail, including why molecular mechanisms and clinical fracture prevention remain different evidential questions. These routes allow the current comparison to focus on coordination rather than repeat every skeletal experiment.
The synthesis also clarifies what a systemic failure claim would require. Severe consequences after global Fgf23 loss are genuine findings in that model. They do not establish that a low vitamin D result in a person has produced the same failure. Nor does normalisation of one marker demonstrate recovery of every organ or endocrine pathway involved.
Conclusion
The selected experiments demonstrate specific endocrine relationships and conditional failures of coordination. Intestinal VDR loss can preserve blood calcium at a skeletal cost; FGF23 loss disrupts phosphate and calcitriol regulation; cartilage and hypothalamic perturbations produce developmental or sex-and-diet-dependent effects. Human cellular interactions and cortisol results remain distinct. Together, the studies support a precise account of endocrine interdependence without establishing universal restoration through supplementation.
Primary source and publication details
Beck J, da Silva Teixeira S, Harrison K, Phillips G, He Y, Sisley S. Paraventricular Vitamin D Receptors Are Required for Glucose Tolerance in Males but Not Females. Frontiers in endocrinology. 2022;13:869678. DOI 10.3389/fendo.2022.869678. PMID 35620386.
Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.
Related reading
Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis
Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis.
Original paper ↗Read more →Dietary phosphorus source reprograms the kidney-intestine axis to dictate calcium-phosphorus efficiency and egg production in aging hens
The decline in egg production in aging hens poses a significant challenge to sustainable poultry production.
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure
Impaired mineral homeostasis and inflammation are hallmarks of chronic kidney disease (CKD), yet the underlying mechanisms of electrolyte regulation during CKD are still unclear.
Original paper ↗Read more →Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients
In this cross-sectional analysis of a multi-ethnic cohort of prevalent hemodialysis patients, association of dietary calcium and prescribed calcium were examined against serum calcium and FGF23.
Original paper ↗Read more →Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose
The vitamin D receptor (VDR) plays a critical role in the regulation of mineral and bone homeostasis.
Original paper ↗Read more →Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function
Plasma approaches metastability with respect to its calcium and phosphate content, with only minor perturbations in ionic activity needed to sustain crystal growth once nucleated.
Original paper ↗Read more →Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis
However, evidence of the causal role of mineral metabolism in CAVS is still lacking.
Original paper ↗Read more →High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss
Phosphate overload contributes to mineral bone disorders that are associated with crystal nephropathies.
Original paper ↗Read more →Loss of 24-hydroxylated catabolism increases calcitriol and fibroblast growth factor 23 and alters calcium and phosphate metabolism in fetal mice
The null fetuses were hypercalcemic, modestly hypophosphatemic (compared to Cyp24a1+/− fetuses only), with 3.5-fold increased calcitriol, 4-fold increased fibroblast growth factor 23 (FGF23), and unchanged parathyroid hormone.
Original paper ↗Read more →Positive association between serum calcium-phosphorus ratio and kidney stone prevalence: Analysis of NHANES data (2007 to 2020)
This study utilized data from the 2007 to 2020 National Health and Nutrition Examination Survey (NHANES), including a total of 34,122 participants.
Original paper ↗Read more →The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis: clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
Complications of mineral bone disease (MBD) are common and contribute to the high morbidity and mortality seen in children with CKD.
Original paper ↗Read more →The High Calcium, High Phosphorus Rescue Diet Is Not Suitable to Prevent Secondary Hyperparathyroidism in Vitamin D Receptor Deficient Mice
In a second study, we aimed to study whether RD with additional 1 and 2% calcium (in total 3 and 4% of the diet) is able to prevent secondary hyperparathyroidism in the VDR KO mice.
Original paper ↗Read more →Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis
Klotho acts as a coreceptor for the phosphaturic hormone fibroblast growth factor-23 (FGF-23) and exists in both a membrane-bound and a soluble form (sKlotho) found in blood and urine.
Original paper ↗Read more →Relationship between Bone Mineral Density and Selected Parameters of Calcium-Phosphate Economy with Dietary Management and Metabolic Control in Polish Pediatric Patients with Classical Homocystinuria: A Preliminary Study
The aim of the study was to examine the relationship of dietary factors, metabolic compensation and selected skeletal parameters in patients with HCU.
Original paper ↗Read more →Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600).
Original paper ↗Read more →Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
We examined factors associated with osteoporosis defined by T-score of ≤ − 2.5, using logistic regression models.
Original paper ↗Read more →Phosphate, calcium, and vitamin D signaling, transport, and metabolism in the endometria of cyclic ewes
However, the effects of P4 and estradiol (E2), with respect to the expression of their receptors PGR and ESR1, respectively, in uterine epithelia on mineral signaling during the estrous cycle has not been investigated.
Original paper ↗Read more →Uptake of Phosphate, Calcium, and Vitamin D by the Pregnant Uterus of Sheep in Late Gestation: Regulation by Chorionic Somatomammotropin Hormone
CSH RNAi Non-IUGR pregnancies had a lower umbilical vein: umbilical artery calcium gradient (p < 0.05) and less cotyledonary calcium (p < 0.05) and phosphate (p < 0.05) compared to Control RNAi pregnancies.
Original paper ↗Read more →Vitamin D and Endocrine Coordination: Compensation and Failure: Study Summary
A concise account of mineral compensation, FGF23 disruption and conditional metabolic and glucocorticoid findings across the selected studies.
Read more →Original sources
Paraventricular Vitamin D Receptors Are Required for Glucose Tolerance in Males but Not Females
Published in Frontiers in endocrinology (2022).
Publication details
Beck J, da Silva Teixeira S, Harrison K, Phillips G, He Y, Sisley S. Paraventricular Vitamin D Receptors Are Required for Glucose Tolerance in Males but Not Females. Frontiers in endocrinology. 2022;13:869678. DOI 10.3389/fendo.2022.869678. PMID 35620386.
Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells
Published in Cellular and molecular life sciences : CMLS (2016).
Publication details
Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization
Published in The Journal of clinical investigation (2012).
Publication details
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
Published in The Journal of clinical investigation (2006).
Publication details
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis
Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis.
Publication details
Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
Published in The Journal of clinical investigation (2004).
Publication details
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.